The American Society of Nuclear Cardiology (ASNC) has released a new information statement with instructions for the safe and effective use of F-18 myocardial perfusion imaging (MPI) radiopharmaceuticals.
The new guidance covers important radiation, clinical, protocol, and interpretation information and follows the recent launch of F-18 flurpiridaz (Flyrcado, GE HealthCare) -- the first PET MPI tracer approved in the U.S. in 30 years. The guide also sets the stage for additional F-18 perfusion tracers currently in development. There are significant differences between these radioisotopes and the tracers imagers have been using, such as rubidium-82 and nitrogen-13 ammonia, the ASNC said in a statement.
The information statement was published recently in the Journal of Nuclear Cardiology and is intended for the entire nuclear cardiology team, the ASNC noted.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
